Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer

Oncology Letters
Mami MuramatsuHideo Nakajima

Abstract

In order to examine the effect on body composition of anticancer drug treatments, the body composition rate in patients being treated with gemcitabine (GEM)-based chemotherapy was measured over time on an outpatient basis with a simple body composition monitor using the bioelectrical impedance (BI) method. The results revealed a significant reduction in the body fat rate (P=0.01) over the course of treatment in patients with pancreatobiliary tract cancer who became unable to continue GEM-based chemotherapy due to progressive disease or a decreased performance status. Meanwhile, no changes were observed in the body composition of control patients with urothelial carcinoma receiving GEM-based chemotherapy. In association with the adverse reactions to GEM and the hematotoxicity profile, a decreased white blood cell count was more likely to occur in body fat-dominant patients (mean fat rate, 25.8%; mean muscle rate, 26.2%), whereas a decreased blood platelet count was more likely to occur in skeletal muscle-dominant patients (mean fat rate, 23.3%; mean muscle rates, 28.7%). The correlation between body composition parameters and the relative dose intensity (RDI) associated with GEM administration was also analyzed. The results reve...Continue Reading

References

Jan 1, 1991·The International Journal of Biochemistry·M Parry-BillingsE A Newsholme
Aug 1, 1990·The American Journal of Clinical Nutrition·R F KushnerD A Schoeller
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Mar 1, 1995·The British Journal of Nutrition·P DeurenbergF J Schouten
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K A NelsonF A Sheehan
Aug 1, 1996·The American Journal of Clinical Nutrition·S H StallM F Michelis
Sep 1, 1996·The American Journal of Clinical Nutrition·L B HoutkooperW H Howell
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Jul 31, 1998·European Journal of Clinical Nutrition·A PietrobelliS B Heymsfield
Mar 19, 1999·JPEN. Journal of Parenteral and Enteral Nutrition·C NuñezS B Heymsfield
Aug 5, 2000·Journal of Applied Physiology·I JanssenR Ross
Sep 5, 2002·British Journal of Clinical Pharmacology·Milena GusellaRoberto Padrini
Aug 9, 1957·Annals of the New York Academy of Sciences·H P SCHWAN, C F KAY
Jun 9, 2005·The American Journal of Clinical Nutrition·Jennifer L KukRobert Ross
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Sep 6, 2005·Cancer Chemotherapy and Pharmacology·Takuji OkusakaToshio Tsuyuguchi
Oct 11, 2005·QJM : Monthly Journal of the Association of Physicians·J N GordonP M Goggin
Feb 17, 2006·European Journal of Clinical Nutrition·Y Oshima, T Shiga
Jun 10, 2006·Nature Clinical Practice. Urology·Claudio PelucchiCarlo La Vecchia
Feb 15, 2007·European Journal of Clinical Nutrition·A A GanpuleI Tabata
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carla M M PradoMichael B Sawyer
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asma SultanaPaula Ghaneh
Aug 19, 2007·International Journal of Clinical Oncology·Akira OzawaMasayoshi Yokoyama
Jan 19, 2008·Journal of Nutritional Science and Vitaminology·Chiyoko UsuiMitsuru Higuchi
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carla M M PradoMichael B Sawyer
Apr 9, 2010·The New England Journal of Medicine·Juan ValleUNKNOWN ABC-02 Trial Investigators
Apr 16, 2010·Age and Ageing·Alfonso J Cruz-JentoftUNKNOWN European Working Group on Sarcopenia in Older People
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Jun 18, 2011·Science·Suman K DasGerald Hoefler
Jul 25, 2012·International Journal of Oncology·Hideo NakajimaYoshiharu Motoo
Dec 5, 2012·Nature Reviews. Clinical Oncology·Kenneth FearonVickie Baracos
Jan 1, 2010·Obesity Research & Clinical Practice·Yoshitake OshimaShinya Kuno

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.